real-time news and commentary for investors
Monday, Sep 2
Isis heart drug helps cut blood fat in trial
- Isis' (ISIS) ISIS-APOCIIIRx reduced levels of triglycerides in blood by up to 75% and of apolipoprotein C-III by 79% in a Phase II study of 28 patients.
- Triglycerides are a type of fat that raises the risk of heart disease, while apolipoprotein C-III prevents triglycerides from being cleared.
- Patients also enjoyed increases of up to 57% in high-density lipoprotein (HDL), or "good," cholesterol.
- ISIS-APOCIIIRx is based on Isis' antisense technology, which inhibits cells from producing proteins that cause diseases. (PR)